MedTrace Logo

4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer

NCT00005047 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 521

Last updated 2017-06-08

Study results available
· View outcomes & findings →

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether combination chemotherapy is more effective than observation alone in treating bladder cancer.

PURPOSE: This randomized phase III trial is studying combination chemotherapy to see how well it works compared to observation alone in treating patients with bladder cancer.

Conditions

Interventions

DRUG

cisplatin

DRUG

doxorubicin hydrochloride

DRUG

methotrexate

DRUG

vinblastine

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • NCIC Clinical Trials Group

    collaborator NETWORK

  • University of Southern California

    collaborator OTHER

  • SWOG Cancer Research Network

    lead NETWORK

Principal Investigators

  • Richard J. Cote, MD, FRCPath · University of Southern California

  • Laurence H. Klotz, MD · Toronto Sunnybrook Regional Cancer Centre

  • Seth P Lerner, MD · Baylor College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-08-31
Primary Completion
2011-03-31
Completion
2014-12-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00005047 on ClinicalTrials.gov